Stock listing
NASDAQ:EWTX Edgewise Therapeutics, Inc. Stock
Home listing (NASDAQ) of Edgewise Therapeutics, Inc.
Follow Edgewise Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:EWTX
$39.91 USD -1.46 (-3.5%)
Close on Nov 20, 2026
- Day range
- $39.71 – $41.40 USDNov 20, 2026
- Volume
- 1.19M sharesNov 20, 2026
- Market cap
- $4.37B USDAt the close on Nov 20, 2026 · price × 109.5M shares outstanding
- 52-week range
- $19.76 – $48.78 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $63.11M USDMedian day 1.34M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EWTX · Home | $39.91 USD | -1.465 (-3.5%) | 1,186,702 | $40.81 | $41.40 | $39.71 | $41.37 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EWTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $39.91 | -1.465 | -3.5% | $40.81 | $41.40 | $39.71 | 1,186,702 | |
| $41.37 | -0.67 | -1.6% | $41.95 | $42.37 | $40.33 | 866,828 | |
| $42.04 | -1.64 | -3.8% | $43.00 | $43.95 | $41.43 | 1,401,210 | |
| $43.68 | -2.25 | -4.9% | $45.48 | $46.00 | $43.43 | 1,279,798 | |
| $45.93 | +0.11 | +0.2% | $45.72 | $46.75 | $44.08 | 1,162,438 | |
| $45.82 | -1.75 | -3.7% | $46.46 | $46.93 | $45.07 | 1,097,354 | |
| $47.57 | +1.04 | +2.2% | $46.28 | $47.85 | $45.62 | 1,343,158 | |
| $46.53 | -2.21 | -4.5% | $46.82 | $47.79 | $44.79 | 1,939,581 | |
| $48.74 | +3.70 | +8.2% | $45.94 | $48.78 | $44.58 | 2,466,519 | |
| $45.04 | +6.17 | +15.9% | $39.71 | $45.76 | $38.05 | 3,608,213 | |
| $38.87 | +1.34 | +3.6% | $43.00 | $43.25 | $36.72 | 5,041,184 | |
| $37.53 | -0.15 | -0.4% | $38.96 | $39.48 | $37.39 | 1,030,868 | |
| $37.68 | -0.43 | -1.1% | $38.73 | $40.41 | $36.70 | 1,859,204 | |
| $38.11 | -0.79 | -2.0% | $38.93 | $39.71 | $37.46 | 1,083,615 | |
| $38.90 | -0.01 | 0.0% | $38.72 | $39.44 | $38.02 | 967,477 | |
| $38.91 | -1.58 | -3.9% | $40.59 | $41.60 | $38.64 | 1,209,604 | |
| $40.49 | +0.96 | +2.4% | $39.53 | $40.56 | $38.96 | 1,629,145 | |
| $39.53 | +0.36 | +0.9% | $39.51 | $40.33 | $39.03 | 691,740 | |
| $39.17 | -0.14 | -0.4% | $39.49 | $40.44 | $38.70 | 1,009,168 | |
| $39.31 | -0.68 | -1.7% | $39.91 | $39.91 | $38.91 | 911,110 | |
| $39.99 | +0.34 | +0.9% | $39.11 | $40.69 | $38.36 | 1,337,725 | |
| $39.65 | -0.10 | -0.3% | $39.95 | $40.78 | $39.45 | 1,828,373 | |
| $39.75 | +1.83 | +4.8% | $38.03 | $40.32 | $37.88 | 2,171,190 | |
| $37.92 | +0.73 | +2.0% | $37.41 | $38.25 | $36.54 | 1,421,580 | |
| $37.19 | -1.01 | -2.6% | $38.28 | $38.28 | $36.70 | 1,305,500 | |
| $38.20 | +1.18 | +3.2% | $37.62 | $38.53 | $37.24 | 1,837,400 | |
| $37.02 | +0.74 | +2.0% | $35.93 | $37.94 | $35.63 | 1,446,100 | |
| $36.28 | -2.17 | -5.6% | $38.17 | $38.35 | $36.08 | 810,100 | |
| $38.45 | -0.61 | -1.6% | $39.12 | $39.36 | $38.32 | 1,536,600 | |
| $39.06 | -0.17 | -0.4% | $39.30 | $40.41 | $38.93 | 1,062,700 | |
| $39.23 | -0.34 | -0.9% | $38.14 | $39.41 | $37.24 | 1,363,500 | |
| $39.57 | -0.45 | -1.1% | $39.66 | $41.06 | $39.40 | 1,446,000 | |
| $40.02 | -0.28 | -0.7% | $40.66 | $41.03 | $39.34 | 1,624,900 | |
| $40.30 | -1.10 | -2.7% | $41.55 | $41.79 | $39.98 | 1,633,800 | |
| $41.40 | +0.92 | +2.3% | $41.01 | $41.94 | $40.42 | 1,459,600 | |
| $40.48 | -0.12 | -0.3% | $40.39 | $41.46 | $39.86 | 1,286,700 | |
| $40.60 | +1.41 | +3.6% | $39.49 | $42.12 | $38.89 | 1,678,300 | |
| $39.19 | -0.60 | -1.5% | $39.53 | $39.58 | $38.51 | 1,920,000 | |
| $39.79 | +0.45 | +1.1% | $39.12 | $40.10 | $39.12 | 2,983,900 | |
| $39.34 | -1.82 | -4.4% | $41.59 | $41.99 | $38.57 | 2,487,500 | |
| $41.16 | +0.11 | +0.3% | $40.28 | $41.94 | $39.74 | 1,378,700 | |
| $41.05 | -3.46 | -7.8% | $44.41 | $44.41 | $39.82 | 2,607,000 | |
| $44.51 | -0.13 | -0.3% | $44.99 | $45.99 | $44.39 | 2,091,200 | |
| $44.64 | -0.68 | -1.5% | $45.70 | $45.98 | $44.09 | 1,178,400 | |
| $45.32 | -1.62 | -3.5% | $46.79 | $46.93 | $45.32 | 1,991,800 | |
| $46.94 | +1.50 | +3.3% | $46.51 | $48.51 | $45.51 | 2,407,800 | |
| $45.44 | +1.81 | +4.1% | $43.37 | $45.60 | $43.37 | 1,683,800 | |
| $43.63 | -0.99 | -2.2% | $44.69 | $45.02 | $42.61 | 2,969,600 | |
| $44.62 | +0.22 | +0.5% | $43.98 | $45.70 | $43.95 | 1,104,400 | |
| $44.40 | +1.50 | +3.5% | $43.54 | $44.80 | $42.90 | 1,404,300 | |
| $42.90 | -0.49 | -1.1% | $42.82 | $43.50 | $42.35 | 788,600 | |
| $43.39 | -0.43 | -1.0% | $43.03 | $44.30 | $42.97 | 707,700 | |
| $43.82 | +0.75 | +1.7% | $42.85 | $44.92 | $42.21 | 1,286,400 | |
| $43.07 | +1.12 | +2.7% | $41.73 | $43.38 | $41.60 | 826,700 | |
| $41.95 | -0.03 | -0.1% | $42.32 | $43.00 | $41.40 | 976,800 | |
| $41.98 | -0.27 | -0.6% | $42.61 | $43.94 | $40.76 | 1,003,500 | |
| $42.25 | +0.48 | +1.1% | $41.59 | $42.64 | $40.82 | 1,040,500 | |
| $41.77 | -0.99 | -2.3% | $42.24 | $42.46 | $40.64 | 1,085,800 | |
| $42.76 | -1.43 | -3.2% | $43.84 | $44.19 | $42.72 | 739,800 | |
| $44.19 | -0.19 | -0.4% | $44.16 | $44.75 | $43.63 | 995,600 | |
| $44.38 | +0.17 | +0.4% | $44.21 | $45.05 | $42.91 | 814,100 | |
| $44.21 | -0.51 | -1.1% | $45.22 | $46.32 | $44.02 | 1,149,200 | |
| $44.72 | +0.54 | +1.2% | $43.67 | $45.44 | $42.59 | 1,042,000 | |
| $44.18 | +0.89 | +2.1% | $43.54 | $44.68 | $43.00 | 1,249,600 | |
| $43.29 | -3.15 | -6.8% | $45.91 | $45.91 | $43.08 | 1,338,600 |
- Ticker
- NASDAQ:EWTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Latest deck · November 2026
Technical Presentation (November 2026)
Technical · 9 slides
Latest news
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Nov 9, 2026
Closed $48.74 (+8.2%) on Nov 9, 2026
Correction: Edgewise Therapeutics
Nov 9, 2026
Closed $48.74 (+8.2%) on Nov 9, 2026
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring
Nov 5, 2026
Closed $38.87 (+3.6%) on Nov 5, 2026
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
Nov 4, 2026
Closed $38.87 (+3.6%) on Nov 5, 2026
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Nov 2, 2026
Closed $38.11 (-2.0%) on Nov 2, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400
Oct 8, 2026
Closed $39.23 (-0.9%) on Oct 8, 2026
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Sep 22, 2026
Closed $44.51 (-0.3%) on Sep 22, 2026
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Aug 24, 2026
Closed $44.72 (+1.2%) on Aug 24, 2026
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Jul 13, 2026
Closed $41.27 (-9.1%) on Jul 13, 2026
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
Jul 13, 2026
Closed $41.27 (-9.1%) on Jul 13, 2026
Edgewise Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 24 in the last 12 months · 125 in all · newest Nov 9, 2026 · oldest 2021
- Decks
- 23 decks · latest November 2026
Where Edgewise Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EWTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:EWTX | BOATS | United States | USD |
Valuation
P/E 4.3× against a median of 24.5×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.63B USD
- P/E
- 4.3×
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.12
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. · NASDAQ:EWTX | US$4.37B | US$2.63B | 4.3× | n/a | n/a | 2.7× | n/a | 0.0× | 1.12 |
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A · SSE:688192 | US$3.90B | US$3.18B | 7.5× | 4.3× | n/a | 5.2× | 69.3% | 0.1× | n/a |
| Definium Therapeutics, Inc. · NASDAQ:DFTX | US$3.88B | US$2.87B | n/a | n/a | n/a | 4.0× | n/a | 0.0× | 1.14 |
| Median of the others | US$4.59B | US$4.02B | 24.5× | 4.9× | 29.9× | 5.8× | −12.2% | 0.1× | 0.90 |
Forecasts
9 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 55.42 USD · Analysts' mean
- EPS, year to Dec 2026
- 7.83 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Nofi | Chief Financial Officer |
| Behrad Derakhshan | Chief Operating Officer |
| John Moore | General Counsel |
| Alan Russell | Director and Co-Founder |
| Badreddin Edris | Director and Co-Founder |
| Joanne M. Donovan | Chief Medical Officer |
| Peter Thompson | Chairman and Co-Founder |
Board
| Director | Role |
|---|---|
| Peter Thompson | Chairman and Co-Founder |
| Alan Russell | Director and Co-Founder |
| Arlene Morris | Director |
| Badreddin Edris | Director and Co-Founder |
| Christopher Martin | Director |
| Jon Root | Director |
| Jonathan C. Fox | Director |
| Kevin Koch | Director |
| Laura Brege | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | +3.6% |
| Q2 2026 | Aug 6, 2026 · Before open | −1.3% |
| Q1 2026 | May 7, 2026 · Before open | −3.8% |
| Q4 2025 | Feb 26, 2026 | +1.1% |
| Q3 2025 | Nov 6, 2025 · Before open | −1.6% |
| Q2 2025 | Aug 7, 2025 · Before open | −4.2% |
| Q1 2025 | May 8, 2025 · Before open | +1.2% |
| Q4 2024 | Feb 20, 2025 · Before open | +1.6% |
| Q3 2024 | Nov 7, 2024 · Before open | −3.3% |
| Q2 2024 | Aug 8, 2024 · Before open | +1.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −4.3% |
| Q4 2023 | Feb 22, 2024 · Before open | −0.7% |
| Q3 2023 | Nov 9, 2023 · Before open | −7.3% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.9% |
| Q1 2023 | May 11, 2023 · Before open | −4.0% |
| Q4 2022 | Feb 23, 2023 · Before open | −2.0% |
| Q3 2022 | Nov 3, 2022 · Before open | +6.8% |
| Q2 2022 | Aug 4, 2022 · Before open | +10.3% |
| Q1 2022 | May 11, 2022 · Before open | −3.8% |
| Q4 2021 | Feb 24, 2022 · Before open | +4.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 9 slides | November 2026 |
| Technical Presentation (October 2026) | Technical | 6 slides | October 2026 |
| Technical Presentation (September 2026) | Technical | 42 slides | Sep 22, 2026 |
| Technical Presentation (August 2026) | Technical | 25 slides | August 2026 |
| World Muscle Society Conference 2025 Symposium | Conference | 55 slides | Oct 8, 2025 |
| Technical Presentation (April 2025) | Technical | 50 slides | Apr 2, 2025 |
| Technical Presentation (December 2024) | Technical | 38 slides | Dec 16, 2024 |
| Technical Presentation (December 2024) | Technical | 37 slides | Dec 16, 2024 |
| Investor Presentation (November 2024) | Investor deck | 57 slides | November 2024 |
| Corporate Update (September 2024) | Corporate update | 43 slides | Sep 19, 2024 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (August 2024) | Technical | 9 slides | August 2024 |
| Conference Presentation (August 2024) | Conference | 29 slides | August 2024 |
| ARCH 2-Year Topline Results Investor Call (April 2024) | Conference | 36 slides | Apr 16, 2024 |
| American Academy of Neurology (AAN) 2024 | Conference | 14 slides | Apr 16, 2024 |
| 28th International Annual Congress of the World Muscle Society 2023 | Conference | 59 slides | Oct 3, 2023 |
| PPMD Annual Conference 2023 | Conference | 22 slides | June 2023 |
| PPMD Annual Conference 2023 | Conference | 10 slides | June 2023 |
| Investor Day (January 2023) | Investor day | 76 slides | Jan 3, 2023 |
| 2023 HCMS Scientific Sessions | Conference | 9 slides | 2023 |
| 27th International Annual Congress of the World Muscle Society 2022 | Conference | 98 slides | Oct 14, 2022 |
| PPMD Connect Conference 2022 | Conference | 15 slides | 2022 |
| New Directions in Biology and Disease of Skeletal Muscle Conference 2021 | Conference | 26 slides | Jun 28, 2021 |
| PPMD Connect Conference 2021 | Conference | 8 slides | June 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$200M · US$20.13 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), Piper Sandler (co-lead), Guggenheim Securities (co-lead), Truist Securities (co-lead) Buyers: Braidwell LP; Cormorant Asset Management; Driehaus Capital Management; Invus; Janus Henderson Investors; MPM BioImpact; OrbiMed; Paradigm BioCapital Advisors; Perceptive Advisors; RA Capital Management; Sofinnova Investments, Inc. Use of proceeds: Potential US launch of sevasemten in Becker, Phase 3 trials of sevasemten and EDG-7500, other R&D, working capital and general corporate purposes | Apr 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Mar 25, 2021.
- Price
- US$16.00 a share
- Shares offered
- 11,000,000 shares of common stock
- Offering size
- US$176 million
- Underwriters' option
- Up to 1,650,000 more shares
- Listing
- EWTX on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, SVB Leerink, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Mar 30, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 18, 2020 |
| Filed publicly | Mar 5, 2021 |
| Amended twice | Newest Mar 24, 2021 |
| Shares registered with an exchange | Mar 17, 2021 |
| Declared effective by the SEC | Mar 25, 2021 |
| Final prospectus, with the price | Mar 26, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 26, 2021 |
| EFFECT · Notice that a registration is effective | Mar 25, 2021 |
| S-1MEF · Registration of more shares for the same offering | Mar 25, 2021 |
| CERT · Exchange's certificate of listing | Mar 25, 2021 |
| S-1/A · Registration statement, amended | Mar 24, 2021 |
| CORRESP · Letter to the SEC | Mar 22, 2021 |
| CORRESP · Letter to the SEC | Mar 22, 2021 |
| S-1/A · Registration statement, amended | Mar 22, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 17, 2021 |
| CORRESP · Letter to the SEC | Mar 8, 2021 |
All 16 filings
| Filing | Filed |
|---|---|
| S-1 · Registration statement | Mar 5, 2021 |
| DRS/A · Draft registration statement, amended | Mar 2, 2021 |
| DRS/A · Draft registration statement, amended | Jan 25, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jan 22, 2021 |
| UPLOAD · Letter from the SEC | Jan 12, 2021 |
| DRS · Draft registration statement | Dec 18, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 26, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 2.27M | 2.29M | 1.73M | 538.0K | 272.0K | 185.0K | 123.0K |
| Gross profit | -2.27M | -2.29M | -1.73M | -538.0K | -272.0K | -185.0K | -123.0K |
| Research and development | 151.4M | 127.0M | 90.9M | 54.0M | 32.2M | 15.0M | 8.62M |
| Selling, general and administrative | 40.0M | 31.9M | 23.5M | 5.47M | 11.0M | 2.21M | 1.30M |
| Operating income | -191.4M | -158.8M | -114.4M | -71.7M | -43.2M | -17.2M | -9.92M |
| Depreciation and amortization | 2.08M | 2.07M | 1.55M | 368.0K | 272.0K | 185.0K | 123.0K |
| EBITDA | -189.3M | -156.8M | -112.8M | -71.3M | -42.9M | -17.0M | -9.80M |
| Interest expense | 4.02M | 272.0K | 69.0K | 0 | |||
| Income before tax | -167.8M | -133.8M | -100.2M | -19.4M | -42.8M | -17.1M | -9.71M |
| Income tax | 4.00K | 3.00K | 4.00K | 0 | 0 | -69.0K | -219.0K |
| Net income | -167.8M | -133.8M | -100.2M | -67.6M | -42.8M | -17.1M | -9.49M |
| Earnings per share, basic | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 | -23.17 | -0.19 |
| Earnings per share, diluted | -1.63 | -1.45 | -1.57 | -1.26 | -1.14 | -23.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 61.1M | 41.7M | 86.1M | 22.0M | 15.6M | 104.9M | 23.7M |
| Short-term investments | 469.0M | 428.5M | 232.3M | 330.0M | 265.2M | 24.2M | 0 |
| Receivables | 251.0K | 548.0K | |||||
| Current assets | 543.4M | 475.5M | 327.0M | 357.0M | 283.8M | 129.6M | 24.0M |
| Property, plant and equipment | 7.83M | 9.50M | 10.4M | 8.53M | 912.0K | 516.0K | 498.0K |
| Total assets | 552.6M | 486.8M | 340.0M | 367.1M | 285.2M | 131.1M | 24.5M |
| Accounts payable | 6.01M | 5.58M | 4.03M | 6.11M | 3.84M | 1.58M | 667.0K |
| Current liabilities | 27.4M | 23.9M | 16.8M | 16.6M | 10.5M | 4.34M | 1.13M |
| Total debt | 3.99M | 4.74M | 5.41M | 4.41M | 160.2M | 40.3M | |
| Total liabilities | 30.3M | 27.6M | 21.2M | 20.4M | 10.8M | 4.34M | 41.4M |
| Shareholders' equity | 522.3M | 459.2M | 318.8M | 346.7M | 274.4M | -33.4M | -16.9M |
| Shares outstanding | 106.2M | 94.8M | 70.5M | 63.3M | 49.5M | 1.01M | 49.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -143.8M | -109.0M | -91.9M | -52.6M | -33.5M | -14.6M | -9.17M |
| Capital spending | -256.0K | -1.31M | -5.75M | -5.55M | -668.0K | -203.0K | -180.0K |
| Free cash flow | -144.1M | -110.3M | -97.7M | -58.2M | -34.2M | -14.8M | -9.35M |
| Cash from investing | -32.8M | -184.7M | 102.9M | -70.6M | -242.2M | -24.4M | -180.0K |
| Cash from financing | 196.1M | 249.3M | 53.2M | 129.6M | 186.4M | 120.3M | 24.8M |
| Share buybacks | 129.9M | 186.4M | |||||
| Change in cash | 19.5M | -44.4M | 64.1M | 6.43M | -89.3M | 81.3M | 15.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 17, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4/A · Change in ownership, amended | Aug 17, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 17, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 17, 2026 | Insider trade | SEC |
| 8-K/A · Current report, amended | Jul 16, 2026 | Current report | SEC |
| 8-K · Current report | Jul 13, 2026 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 1, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 7, 2026 | Offer document | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 27, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 27, 2026 | Other filings | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 29, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 8-K · Current report | Nov 10, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | May 14, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2025 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Apr 2, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2025 | Material contract | SEC |
| 8-K · Current report | Apr 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 21, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 26, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Nov 7, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 23, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 23, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 8-K · Current report | May 10, 2024 | Material contract | SEC |
| S-3ASR · Registration statement | May 10, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 4 · Change in ownership | May 7, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 7, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 7, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 7, 2024 | Management or board change | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
This page holds 200 of 426 filings. Open Filings
Cap table
Built by 6ix from Edgewise Therapeutics, Inc.’s releases · as of Oct 31, 2026
- Common shares
- 109,482,763
- Fully diluted
- 109,482,763
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 109,482,763 | Oct 31, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 31, 2026 | 109,482,763 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Laura Brege Other companies: Mirum Pharmaceuticals, Inc. (Board Member · Since at least Jul 17, 2019); ACADIA Pharmaceuticals Inc. (Director · Since at least Jun 10, 2016); Pacira BioSciences, Inc. (Director · Since at least Jun 6, 2016); Aratana Therapeutics Inc (Director · Jun 24, 2016 – Jul 27, 2018 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Dynavax Technologies Corporation (Director · May 31, 2016 – May 30, 2019 · Past) | Director · Since at least Mar 25, 2021 |
| Arlene Morris Other companies: Palatin Technologies, Inc. (Director · Since at least Jun 22, 2022); Viridian Therapeutics, Inc. (Chief Executive Officer, Willow Advisors · Since at least Jun 8, 2022); Cogent Biosciences, Inc. (Director · Since at least Jun 7, 2022); Viveve Medical, Inc. (Director · Jan 3, 2023 – Jan 3, 2023 · Past) | Director · Since at least May 6, 2024 |
| Christopher Martin Other companies: Achieve Life Sciences, Inc. (Director · Since at least May 11, 2026); Oruka Therapeutics, Inc. (Director · Since at least Dec 11, 2025) | Director · Since at least Nov 19, 2025 |
| Jonathan C. Fox Other companies: Eidos Therapeutics Inc (See Remarks · Jun 19, 2018 – Jan 26, 2021 · Past); MyoKardia Inc (Chief Medical Officer · Oct 28, 2015 – Apr 29, 2016 · Past) | Director · Since at least Mar 2, 2023 |
| Jonathan Root Other companies: Carlsmed, Inc. (Director · Since at least Jul 22, 2025); Omada Health, Inc. (Director · Since at least Jun 5, 2025) | Director · Since at least Jun 16, 2025 |
| Marc Semigran Other companies: ProKidney Corp. (Director · Jun 29, 2021 – Jun 29, 2021 · Past); MyoKardia Inc (Chief Medical Officer · Dec 1, 2016 – Feb 8, 2019 · Past) | Chief Development Officer · Dec 19, 2022 – Dec 24, 2024 · Past |
| Michael Nofi Other companies: SpringWorks Therapeutics Inc (Chief Accounting Officer · Since at least Nov 11, 2019); Perfumania Holdings Inc (CFO · Apr 28, 2017 – Apr 28, 2017 · Past) | Chief Financial Officer · Since at least Nov 10, 2025 |
| Badreddin Edris Other companies: SpringWorks Therapeutics Inc (Chief Operating Officer · Since at least Jan 4, 2024) | Director and Co-Founder · Since at least Jun 10, 2024 |
| Joanne M. Donovan Other companies: Astria Therapeutics Inc (CMO; SVP Clinical Development · Jun 24, 2015 – Feb 12, 2020 · Past) | Chief Medical Officer · Since at least Apr 26, 2021 |
| John Moore Other companies: Alpine Immune Sciences Inc (Director · Jun 16, 2015 – Sep 12, 2016 · Past) | General Counsel · Since at least Mar 25, 2021 |
All 15 people
| Person | Seat |
|---|---|
| Kevin Koch Other companies: Viridian Therapeutics, Inc. (Director · Jun 27, 2018 – May 21, 2020 · Past) | Director · Since at least Mar 25, 2021 |
| Alan Russell | Director and Co-Founder · Since at least May 1, 2025 |
| Behrad Derakhshan | Chief Operating Officer · Since at least May 1, 2025 |
| Jon Root | Director · Since at least Nov 4, 2026 |
| Peter Thompson | Chairman and Co-Founder · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Edgewise Therapeutics, Inc.